Cargando…

Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)

BACKGROUND: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Guffon, N., Pettazzoni, M., Pangaud, N., Garin, C., Lina-Granade, G., Plault, C., Mottolese, C., Froissart, R., Fouilhoux, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847591/
https://www.ncbi.nlm.nih.gov/pubmed/33517895
http://dx.doi.org/10.1186/s13023-020-01644-w
_version_ 1783644952512692224
author Guffon, N.
Pettazzoni, M.
Pangaud, N.
Garin, C.
Lina-Granade, G.
Plault, C.
Mottolese, C.
Froissart, R.
Fouilhoux, A.
author_facet Guffon, N.
Pettazzoni, M.
Pangaud, N.
Garin, C.
Lina-Granade, G.
Plault, C.
Mottolese, C.
Froissart, R.
Fouilhoux, A.
author_sort Guffon, N.
collection PubMed
description BACKGROUND: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-term outcomes are known to be improved by HSCT, the long-term cognitive, adaptive and psychosocial functional outcomes of children with (MPSI-H) post-HSCT are not well documented. This manuscript focuses on retrospective long-term follow-up (7–33 years) of 25 MPSI-H patients, transplanted between 1986 and 2011. RESULTS: The median age at transplantation was 21 months (range 12–57 months). Except for one death, all successfully transplanted MPSI-H patients surviving at least 1 year after HSCT are alive to-date, with a median age of 21 years (range 8–36 years) at the last follow-up evaluation. A majority of HSCT grafts were bone marrow transplants (BMT), resulting in durable full chimerism in 18 (72%). Pre-HSCT, the onset of first symptoms occurred very early, at a median age of 3 months (range birth-16 months). The most prevalent symptoms before MPSI-H diagnosis involved progressive dysostosis multiplex; almost all patients suffered from hip dysplasia and thoracolumbar spine Kyphosis. Despite HSCT, considerable residual disease burden and ensuing corrective surgical interventions were observed in all, and at every decade of follow-up post HSCT. Late-onset psychiatric manifestations were significant (n = 17 patients; 68%), including depression in 13 patients at a median onset age of 18 years (range 13–31 years), hyperactivity and attention deficit disorder (n = 4), and multiple acute psychotic episodes (APE), independent of depression observed (n = 3) at a median onset age of 18 years (range 17–31 years). The adult Welscher Intelligence Scale results (n = 16) were heterogenous across the four scale dimensions; overall lower scores were observed on both working memory index (median WMI = 69.5) and processing speed index (median PSI = 65), whereas verbal comprehension index (median VCI = 79) and perceptual reasoning index (median PRI = 74) were higher. CONCLUSION: With advanced treatment options, MPSI-H are living into 3rd and 4th decades of life, however not disease free and with poor adaptation. Residual disease (loss of mobility, limited gross and fine motor skills; low cognitive ability; suboptimal cardiopulmonary function, vision and hearing) negatively impacts the quality of life and psychosocial functioning of affected individuals.
format Online
Article
Text
id pubmed-7847591
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78475912021-02-01 Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT) Guffon, N. Pettazzoni, M. Pangaud, N. Garin, C. Lina-Granade, G. Plault, C. Mottolese, C. Froissart, R. Fouilhoux, A. Orphanet J Rare Dis Research BACKGROUND: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-term outcomes are known to be improved by HSCT, the long-term cognitive, adaptive and psychosocial functional outcomes of children with (MPSI-H) post-HSCT are not well documented. This manuscript focuses on retrospective long-term follow-up (7–33 years) of 25 MPSI-H patients, transplanted between 1986 and 2011. RESULTS: The median age at transplantation was 21 months (range 12–57 months). Except for one death, all successfully transplanted MPSI-H patients surviving at least 1 year after HSCT are alive to-date, with a median age of 21 years (range 8–36 years) at the last follow-up evaluation. A majority of HSCT grafts were bone marrow transplants (BMT), resulting in durable full chimerism in 18 (72%). Pre-HSCT, the onset of first symptoms occurred very early, at a median age of 3 months (range birth-16 months). The most prevalent symptoms before MPSI-H diagnosis involved progressive dysostosis multiplex; almost all patients suffered from hip dysplasia and thoracolumbar spine Kyphosis. Despite HSCT, considerable residual disease burden and ensuing corrective surgical interventions were observed in all, and at every decade of follow-up post HSCT. Late-onset psychiatric manifestations were significant (n = 17 patients; 68%), including depression in 13 patients at a median onset age of 18 years (range 13–31 years), hyperactivity and attention deficit disorder (n = 4), and multiple acute psychotic episodes (APE), independent of depression observed (n = 3) at a median onset age of 18 years (range 17–31 years). The adult Welscher Intelligence Scale results (n = 16) were heterogenous across the four scale dimensions; overall lower scores were observed on both working memory index (median WMI = 69.5) and processing speed index (median PSI = 65), whereas verbal comprehension index (median VCI = 79) and perceptual reasoning index (median PRI = 74) were higher. CONCLUSION: With advanced treatment options, MPSI-H are living into 3rd and 4th decades of life, however not disease free and with poor adaptation. Residual disease (loss of mobility, limited gross and fine motor skills; low cognitive ability; suboptimal cardiopulmonary function, vision and hearing) negatively impacts the quality of life and psychosocial functioning of affected individuals. BioMed Central 2021-01-31 /pmc/articles/PMC7847591/ /pubmed/33517895 http://dx.doi.org/10.1186/s13023-020-01644-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Guffon, N.
Pettazzoni, M.
Pangaud, N.
Garin, C.
Lina-Granade, G.
Plault, C.
Mottolese, C.
Froissart, R.
Fouilhoux, A.
Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title_full Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title_fullStr Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title_full_unstemmed Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title_short Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)
title_sort long term disease burden post-transplantation: three decades of observations in 25 hurler patients successfully treated with hematopoietic stem cell transplantation (hsct)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847591/
https://www.ncbi.nlm.nih.gov/pubmed/33517895
http://dx.doi.org/10.1186/s13023-020-01644-w
work_keys_str_mv AT guffonn longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT pettazzonim longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT pangaudn longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT garinc longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT linagranadeg longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT plaultc longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT mottolesec longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT froissartr longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct
AT fouilhouxa longtermdiseaseburdenposttransplantationthreedecadesofobservationsin25hurlerpatientssuccessfullytreatedwithhematopoieticstemcelltransplantationhsct